Goldman Sachs analyst Corinne Johnson started Structure Therapeutics (GPCR) with an Early-Stage Biotech rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Holds 2025 Annual Shareholders Meeting
- Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating
- Structure Therapeutics price target raised to $80 from $75 at H.C. Wainwright
- Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating